6 July 2011: Vantia Therapeutics announces £4 million fund raising

Vantia Therapeutics raises £4 million to fund clinical development of lead compounds.

9 June 2010: Vantia appoints new CEO

Vantia Therapeutics announces that it has appointed Andrew Crockett to the position of Chief Executive Officer.

6 March 2010: Vantia reveals VA111913 structure

Vantia Therapeutics reveals structure of its novel small molecule treatment for dysmenorrhoea, VA111913, at the ACS National Meeting in San Francisco, USA.